{"schema_version":"secwatch.filing_event.v1","accession":"0001200375-23-000017","form_type":"8-K","ticker":"CDXS","cik":"0001200375","company_name":"CODEXIS, INC.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.169649+00:00","generated_at":"2026-06-15T20:42:02.354748+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Codexis Q1 revenue $13M (-63% YoY); net loss $22.6M; lowers product revenue guidance","bullets":["Q1 total revenue $13.0M (ex-PAXLOVID -8% YoY); net loss $22.6M ($0.34/share) vs $8.4M loss in Q1 2022.","Product revenue guidance lowered to $30-$35M from $35-$40M; gross margin guided 55-65% (down from prior).","R&D revenue guidance raised to $28-$33M, includes $5M non-cash Pfizer license revenue in Q2 2023.","CDX-7108 Phase 1 interim data showed improved lipid absorption; IND filing by end 2023, Phase 2 H1 2024.","Cash $102.8M at March 31, 2023; estimated runway through end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001200375-23-000017","json":"https://secwatch.observer/filing/0001200375-23-000017.json","markdown":"https://secwatch.observer/filing/0001200375-23-000017.md","text":"https://secwatch.observer/filing/0001200375-23-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1200375/000120037523000017/0001200375-23-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1200375/000120037523000017/cdxs-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:42:02.354748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b49ad26999e3dbd4d4166395ccf050a669bf2e3","claim":"CODEXIS, INC. updated its fiscal year 2023 guidance (reaffirmed).","evidence_excerpt":"The Company reiterated its 2023 total revenue guidance range of $63 million to $68 million, excluding enzyme sales related to PAXLOVIDTM, with adjustments to the mix of product revenues versus R&D revenues.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1200375/000120037523000017/0001200375-23-000017-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"6f262ec1e898ca39afd181a3b6ceeb82098343e3","claim":"CODEXIS, INC. reported first quarter ended March 31, 2023 results: revenue $13.0 million, net income $22.6 million, EPS $0.34 per share. Guidance reaffirmed.","evidence_excerpt":"Total revenues for first quarter 2023 were $13.0 million compared to $14.0 million in the prior year, excluding enzyme sales related to PAXLOVIDTM of $0 and $21.3 million in each period, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1200375/000120037523000017/0001200375-23-000017-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$13.0 million"},{"label":"Net income","value":"$22.6 million"},{"label":"EPS","value":"$0.34 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}